Entries by Thomas Gabrielczyk

Aseptic Closed Small-Volume Processing: Today’s Option`s

Small-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.

Let Excelya recruit the right people for the early phase

Early phase clinical trials require expert support, often across many service areas and specialisms. Recruitment for trials can be complicated, with less flexibility and higher costs as you attempt to acquire top talent on a project-only basis. That’s why CROs are becoming increasingly indispensable. CROs offer fully formed, multi-skilled teams ready to go, who you can bring on board as and when needed.

Graphene

Graphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.

Advancing cancer immunotherapy

Single cell multiomics has the capacity to address key challenges to developing cell and gene therapies, specifically CAR T-cell therapies. Hear how leading cancer immunotherapy researchers are using these approaches for characterizing the leukapheresis and infusion product, studying the evolution of the cell product in vivo, identifying and defining mechanisms of resistance, and discovering next-generation cell therapies.

Managing risks and finding opportunities through logistics

By applying the expertise, best practice, and emerging technologies of the logistics industry,  biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.